breast cancer
Conditions
Interventions
Observation group:none
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Females, aged 18-75 years, with an ECOG performance status of 0-1; 2. Pathologically confirmed TNBC (ER < 1%, PR < 1%, HER2 IHC 0-2+, excluding HER2 ISH+); 3. Breast cancer stage T1-3N0-1M0; 4. Receiving neoadjuvant immunotherapy combined with chemotherapy, where immunotherapy includes PD-1 or PD-L1 monoclonal antibodies.
Exclusion criteria
Exclusion criteria: 1. Insufficient neoadjuvant immunotherapy of fewer than 4 treatment cycles due to various reasons; 2. Malignant tumors originating from other organs that have metastasized to the breast, or presence of other unresolved malignant tumors; 3. Pregnancy-associated breast cancer; 4. Lack of pathological complete response data during follow-up; 5. Insufficient or inaccessible samples required for ImPredict score/IPPI model assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve for pathological complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| distant recurrence-free survival; | — |
Countries
China
Contacts
Public ContactZongchao Gou
West China Hospital, Sichuan University
Outcome results
None listed